('sars-cov-2', 36);('omicron ba.1', 24);('covid-19', 21);('voc', 19);('delta', 17);('supplementary materials', 17);('figure', 17);('cri', 17);('netherlands', 16);('hospital admissions', 16);('january', 14);('breakthrough infections', 10);('tilburg', 9);('utrecht', 9);('jan', 9);('jul', 8);('oct', 8);('data', 8);('supplementary', 7);('vocs', 7);('february', 7);('alpha', 6);('primary infections', 6);('rst wave', 6);('google', 6);('susceptible individuals', 6);('rivm dashboard', 6);('total infections', 6);('hospitalization burden', 5);('mobility data', 5);('dutch', 5);('delta omicron', 5);('primary infection', 5);('case detection rates', 5);('van der', 5);('e t', 5);('o.b', 5);('age-specic burden', 4);('firstly', 4);('secondly', 4);('apr', 4);('% credible intervals', 4);('a7', 4);('omicron', 4);('october', 4);('immune status', 4);('age group', 4);('april', 4);('github', 4);('covid-', 4);('g.r', 4);('otilia boldea', 3);('econometrics', 3);('or', 3);('economics', 3);('management', 3);('columbia', 3);('usa', 3);('primary care', 3);('medical center', 3);('p.o', 3);('understanding', 3);('age-specic epidemiology', 3);('dierent age groups', 3);('transmission [', 3);('serological surveys', 3);('thirdly', 3);('modelling', 3);('pcr', 3);('young children', 3);('quantiles model mean data', 3);('environment', 3);('rivm', 3);('parameter', 3);('sensitivity analyses', 3);('study period', 3);('2020jul 2020oct 2020jan 2021apr 2021jul 2021oct 2021jan', 3);('cri model mean data feb', 3);('27mar 12mar 26apr 09apr', 3);('reported', 3);('age-specic', 3);('age', 3);('national infections', 3);('adults', 3);('fraction', 3);('breakthrough infection', 3);('june', 3);('september', 3);('dataset', 3);('hnewobs', 3);('data https', 3);('disease', 3);('s2', 3);('public health', 3);('coronavirus', 3);('lancet', 3);('nature', 3);('systematic review', 3);('national academy', 3);('epidemiology', 3);('nature communications', 3);('pei', 3);('england', 3);('klinkenberg d', 3);('s.p', 3);('j.s', 3);('substantial feedback', 3);('ganna rozhnova', 2);('york', 2);('ci', 2);('g.rozhnova @ umcutrecht.nl', 2);('tilburg univer', 2);('o.boldea @ tilburguniversity.edu', 2);('immunological landscape', 2);('ba.1', 2);('poor predictor', 2);('statistics data', 2);('european countries', 2);('public health policy', 2);('non-pharmaceutical interventions [', 2);('vaccination [', 2);('nether', 2);('ensemble adjustment', 2);('kalman', 2);('national statistics data', 2);('demographic data', 2);('control measures', 2);('transmission dynamics', 2);('delta omicron d', 2);('estimated', 2);('posterior ensemble values', 2);('national institute', 2);('table 1and', 2);('solid vertical lines', 2);('genetic variant data', 2);('time-dependent', 2);('january31', 2);('primary vaccination series', 2);('2020jun 2021jan', 2);('national seroprevalence', 2);('hospitalizations figure', 2);('black lines', 2);('child ren', 2);('wild-type period', 2);('infectio ns', 2);('adult population', 2);('adolescents', 2);('burden', 2);('synthetic outbreak', 2);('original data', 2);('assess parameter identiability', 2);('synthetic outbreaks', 2);('across', 2);('model congurations', 2);('true parameters', 2);('seroprevalence estimates', 2);('sars- cov-2', 2);('uk', 2);('non-pharmaceutical interventions', 2);('national seroprevalence data', 2);('transmission model', 2);('age-specic parameters', 2);('metapopulation model', 2);('additional', 2);('overview', 2);('onward https', 2);('dutch railways', 2);('ns', 2);('additional information', 2);('school closures', 2);('contacts c', 2);('r= 1,2,3', 2);('survey rounds', 2);('age-specic force', 2);('vaccination', 2);('mobility', 2);('state variables', 2);('sections', 2);('figures', 2);('march', 2);('model parameters', 2);('synthetic data', 2);('train mobility data', 2);('klis', 2);('] world health organization', 2);('liu y', 2);('jit', 2);('bmc', 2);('sharma', 2);('mindermann', 2);('government interventions', 2);('inferring', 2);('wang x', 2);('dorp ch', 2);('risk factors', 2);('infectious diseases', 2);('kissler sm', 2);('lipsitch', 2);('grad yh', 2);('advances', 2);('sah p', 2);('sars-cov-2 infection', 2);('tran kiem', 2);('medicine', 2);('goldstein e', 2);('boven', 2);('kandula', 2);('coeng le', 2);('vlas sj', 2);('bertuzzo e', 2);('mari', 2);('miccoli', 2);('italy', 2);('bmc medicine', 2);('presanis', 2);('bayesian', 2);('centre', 2);('disease prevention', 2);('ainslie kec', 2);('interface', 2);('european union', 2);('a.a.', 2);('arxiv:2212.13470v1 [ physics.soc-ph ]', 1);('dec', 1);('2022age-specic transmission dynamics', 1);('th e rst', 1);('phd1', 1);('amir alipoor', 1);('msc1', 1);('sen pei', 1);('phd2', 1);('jerey shaman', 1);('phd2,3', 1);('phd4,5,6', 1);('center', 1);('environmental', 1);('mailman', 1);('ublic health', 1);('climate', 1);('4julius center', 1);('medic', 1);('integrative', 1);('faculdade', 1);('d e', 1);('universidade', 1);('lisboa', 1);('lisbon', 1);('portugal', 1);('complex systems studies', 1);('ccss', 1);('netherlands december', 1);('corresponding', 1);('ganna rozhnova julius', 1);('utrecht p.o', 1);('netherlands email', 1);('center tilburg', 1);('netherlands e-mail', 1);('pandemic manifest', 1);('multiple waves', 1);('complex interactions', 1);('non-pharmaceut ical interventions', 1);('age-specic epide miology', 1);('policy decisions', 1);('true infections', 1);('o micron', 1);('true infect ion burden', 1);('tota l infection', 1);('successive variants', 1);('naive indi viduals', 1);('unders tand age-specic epidemiology', 1);('successive waves', 1);('random community surveys unc', 1);('basic surveillance', 1);('introduction', 1);('complex spatio-temporalpattern', 1);('multiple waves [', 1);('hospitalizations [', 1);('notableexampleistheagedistributionofreportedcaseswithmuchlo wernumberofcasesamongyoungerindividuals', 1);('wild-type variant', 1);('pandemic [', 1);('inf ection burden varies', 1);('measures [', 1);('age-specic hospitalization burden [', 1);('] underpins prioritization', 1);('full reconstruction', 1);('age-s pecic burden', 1);('surveillance systems', 1);('fact coupledwith', 1);('evidence ofasymptomaticin fection [', 1);('] undermines', 1);('capturethe trueburden ofinfections amongdierent agegrou ps', 1);('few', 1);('representative serological surveys', 1);('characteriz eprior infection burden [', 1);('immunolog ical landscape', 1);('complex [', 1);('implementing', 1);('representative serosurveys', 1);('estimate popula tion immunity', 1);('inf ections', 1);('additional factors', 1);('vo cs', 1);('population immunity', 1);('s easonality', 1);('] complicate estimation', 1);('important insights', 1);('temporal cha nges', 1);('specic countries [ 13,20,24,2630 ]', 1);('available evidence [ 24,28,29 ]', 1);('reconstruct age-specic epidemiology [', 1);('specic periods', 1);('rst wave [', 1);('variants [', 1);('data accumulate', 1);('formalevaluations basedon mathematical m odels calibratedto dierent types', 1);('observational data [ 13,27,30 ]', 1);('hos pitalizations', 1);('long periods', 1);('reconstructthe epidemiologyofsars-cov-2', 1);('landsoverthe rst 23months ofthe pandemic', 1);('n age-', 1);('transmis- sion model', 1);('variousdata sources', 1);('supplementary mat', 1);('ourtting', 1);('bayesianevidence', 1);('synthesis [ 13,26,3638 ]', 1);('lter [ 27,39,40 ]', 1);('individual countries', 1);('vaccination coveragedata', 1);('socia l contact matrices', 1);('regional train', 1);('se condary schoolchildren versus', 1);('popula- tion [', 1);('age-dependent transmission eects [ 3,14,17,4144 ]', 1);('abo ve', 1);('model structure', 1);('current knowledge', 1);('w hich suggests', 1);('potential changes', 1);('re- infections', 1);('breakthrough infections [', 1);('regional stratication', 1);('real-world mobility', 1);('infection stay', 1);('previous', 1);('epidem ic models', 1);('epidemiological para meters [', 1);('hospitalizations', 1);('cri model mean data', 1);('total apr', 1);('adults apr', 1);('adolescents apr', 1);('children figure', 1);('national daily hospital admissions', 1);('p urple', 1);('regions correspond', 1);('% quantile s', 1);('hospital admission data', 1);('dat', 1);('intensive care evaluation', 1);('hea', 1);('parsimonious model', 1);('robust estimation', 1);('key time-var', 1);('epidemiological parameters compatible', 1);('regional epidemiology', 1);('po st-vaccination periods', 1);('supplementary tables a1a6', 1);('figures a1a4', 1);('ident iability', 1);('model reproduces', 1);('regionalhospital admissions', 1);('adolescentsand adults', 1);('wavesthat occurredfromthe rst ocialcaseon', 1);('february27', 1);('supplementary figures a5a7', 1);('national level', 1);('nu mber', 1);('wave s', 1);('vacc ination program', 1);('clinical disease', 1);('children [ 3,13,14,26 ]', 1);('rst booster campaign', 1);('p eriod', 1);('d ay', 1);('large st', 1);('seroprevalenc e', 1);('age-specic seroprevalence', 1);('b-d', 1);('supplementary figures a8a16', 1);('infectio n.', 1);('fast antibodies decay', 1);('fast new infections', 1);('national seropre', 1);('adolesce nts', 1);('a8', 1);('th e rst wave', 1);('candd', 1);('throughout', 1);('ve waves', 1);('fig', 1);('adolescents d', 1);('rst ve waves', 1);('age grou p', 1);('ado lescents', 1);('muc h', 1);('5sep 2020jun 2021jan 202200.20.40.60.81fraction', 1);('seropositive', 1);('cri adults mean data sep', 1);('cri adolescents mean data sep', 1);('mean dataa', 1);('seroprevalence apr', 1);('cases adults apr', 1);('cases adolescents apr', 1);('cases children figure', 1);('inset', 1);('low case', 1);('lines repres ent', 1);('r egions correspond', 1);('% quantiles', 1);('posterior e nsemble values', 1);('black dots', 1);('th e scale', 1);('cand d. wild-type alpha delta omicron00.20.40.60.8 fraction', 1);('reported adults', 1);('unreported adolescents', 1);('reported adolescents', 1);('unreported', 1);('unreporteda', 1);('infections wild-type alpha delta omicron00.20.40.60.81fraction', 1);('adolescents childrenb', 1);('d hospital admissions', 1);('6the study period', 1);('subpopulat ions', 1);('age-specic distribution', 1);('national cases whic h', 1);('hospital admissio ns', 1);('model estimates temporal changes', 1);('age-specic contac t rates', 1);('w ith', 1);('mobility patterns', 1);('age-sp ecic distribution', 1);('figur', 1);('supplementary tables a9a10', 1);('n ational infections', 1);('omicr', 1);('total infe ctions', 1);('dark turquoise', 1);('betwee n', 1);('majority o f', 1);('f rom', 1);('adult cases', 1);('age-specic co ntribution', 1);('total hospital admissions', 1);('minor fraction', 1);('circula tion', 1);('a11', 1);('wild-type alpha delta omicron00.050.10.150.20.250.30.350.4fraction', 1);('infections wild-type alpha delta omicron00.511.522.53hospitalized', 1);('total population', 1);('age grou p.', 1);('eac h age group', 1);('semble values', 1);('7age-specic burden stratication', 1);('nd hospital admissions', 1);('supplementary tables a12a13', 1);('infe ctions', 1);('figure4a', 1);('hospital admission burden', 1);('primary infection versus', 1);('fter re-infection', 1);('alph', 1);('adults f', 1);('b reakthrough infections', 1);('simila', 1);('r dynamics', 1);('breakthrough infections/re-infections', 1);('primary infec tions', 1);('breakthroug h infections/re-infections', 1);('high vaccination coverage', 1);('hospitalization probability', 1);('v ery', 1);('extreme case', 1);('adult populat ion', 1);('sma ller', 1);('naive population', 1);('primar y infections', 1);('r e-infections', 1);('omicron ba.1 vocs', 1);('vaccination schedule', 1);('high durin g', 1);('young child ren', 1);('primary infection s', 1);('slight increase', 1);('posterior distribution', 1);('model parame ters', 1);('system identiability', 1);('hospitalization data', 1);('similar trends', 1);('par ameter combination', 1);('re-estimate th e model parameters', 1);('sensitivity', 1);('model parameters th', 1);('methods', 1);('results wer e', 1);('seroprevalence esti- mates', 1);('v alues', 1);('native calibrations', 1);('discussion', 1);('reconstru ct', 1);('complex interac tion', 1);('non-pharmaceutical inter- ventions', 1);('st udy', 1);('age groups r', 1);('overall improve- ment', 1);('gener ally', 1);('true incidence', 1);('total infection', 1);('succes sive', 1);('increase demonstrates', 1);('substantial burdens', 1);('additional pressure', 1);('healthcare systems', 1);('primary inf ections', 1);('naive individuals', 1);('periods primary infections', 1);('com mon', 1);('vaccination roll-out', 1);('t hat', 1);('age groups', 1);('breakthrou gh infections', 1);('identie d case data', 1);('wav e', 1);('primary infections versus re-infections', 1);('th e population stratication', 1);('computational eciency', 1);('model distinguishes', 1);('naive indiv iduals', 1);('natural infection', 1);('comprehensive applicatio n', 1);('ecient inference-', 1);('h ospitalization burden', 1);('immune status [ 13,31,4853 ]', 1);('pandem ic years', 1);('framewor k', 1);('common surveillance', 1);('compared', 1);('studies [ 24,27,28,54 ]', 1);('model contacts', 1);('elementary schools', 1);('secondary schools', 1);('reliable disentanglement', 1);('estimate contact changes', 1);('non-pharmaceutical interve ntions', 1);('school environment', 1);('proxy mobility measures [', 1);('train mobility', 1);('transit stations', 1);('o bserve', 1);('ocial implem entation', 1);('behavioral changes', 1);('age-specic contacts', 1);('intervention [ 13,26,56 ]', 1);('constant o ver time', 1);('retrospective', 1);('elementar y', 1);('secondary schoolchildren', 1);('future work', 1);('regional hospital admissions', 1);('data sources', 1);('moveme nt', 1);('infection s', 1);('inference method', 1);('secondary role', 1);('tr ansmission dynamics', 1);('low frequency', 1);('studies [', 1);('freque ncy', 1);('incorporation', 1);('sewage w ater', 1);('drastic changes', 1);('surv eillance', 1);('projections o f transmission dynamics', 1);('ourmodelcouldalsobeextendedtoquantifysar s-cov-2infectionandcovid-19hospitalization', 1);('vulnerable populations', 1);('chronic condition s [', 1);('adolescen ts', 1);('early stages', 1);('susceptibilit y', 1);('initial period', 1);('observe g ood identication', 1);('age categories', 1);('age categories relevant', 1);('bu rden', 1);('individuals travel', 1);('mobility m ay', 1);('age-specic para meters', 1);('10primary versus breakthrough infections', 1);('time period', 1);('large proportion', 1);('sars', 1);('-cov-2 transitions', 1);('population [', 1);('dierentiate betwe', 1);('immunity classes', 1);('various boosters', 1);('hybrid immunity [', 1);('transmissionmode l', 1);('co untries', 1);('random community surveys', 1);('basic surve illance', 1);('hospitalization s', 1);('methods overview', 1);('nationa l statistics data', 1);('regional tra', 1);('vaccination coverage data', 1);('social contact matrices', 1);('model t', 1);('ication data', 1);('age-and province-stratiedcov', 1);('id-19hospital', 1);('admissiondata forthe', 1);('median dates', 1);('model input', 1);('commut ers', 1);('national train data', 1);('full v accinations', 1);('age category', 1);('november', 1);('weekly genetic', 1);('december', 1);('non-school contact matrices', 1);('model analyses', 1);('mat lab', 1);('versions 2021a', 1);('stata', 1);('se v16', 1);('mod el', 1);('entire sample period runs', 1);('windows', 1);('dell', 1);('intel cor', 1);('e i5 processor', 1);('data table1gives', 1);('details o n', 1);('sec', 1);('data notationsource population', 1);('age group k', 1);('ik cbs', 1);('province i https', 1);('inewobs', 1);('//data.rivm.nl/covid-19/covid-19_casus_landel ijk.csv', 1);('daily hospital admissions', 1);('rivmdata', 1);('//data.rivm.nl/covid-19/covid-19_ziekenhuisop names.csv https', 1);('//data.rivm.nl/covid-19/covid-19_ziekenhuisop names_tm_03102021.csv', 1);('//data.rivm.nl/covid-19/covid-19_ziekenhuis_i c_opnames_per_leeftijdsgroep.csv https', 1);('//data.rivm.nl/covid-19/covid-19_ziekenhuis_i c_opnames_per_leeftijdsgroep_tm_03102021.csv', 1);('seroprevalence', 1);('rivm pienter corona', 1);('serosurvey', 1);('rounds h= 1,2,3,4 https', 1);('median', 1);('inclusion time tser h', 1);('seropositive serhk sample size nhk', 1);('train', 1);('mij', 1);('provinces iandj', 1);('commuters wij cbs', 1);('province jtoi https', 1);('mobility yg https', 1);('daily vaccinations', 1);('vik', 1);('//data.rivm.nl/covid-19/covid-19_vaccinatiegr aad_per_gemeente_per_week_leeftijd.csv', 1);('//www.rivm.nl/en/covid-19-vaccination/archive -covid-19-vaccination-figures-2021', 1);('booster', 1);('transition function gb', 1);('//www.rivm.nl/en/covid-19-vaccination/archive -covid-19-vaccination-figures-2022', 1);('variants', 1);('transition function g', 1);(',o }', 1);('//data.rivm.nl/covid-19/covid-19_varianten.cs v', 1);('contact', 1);('elementary school contacts cikk', 1);('es', 1);('secondary', 1);('school contacts cikk', 1);('ss', 1);('all-setting', 1);('non-school', 1);('indices i', 1);('... ,12', 1);('indices k', 1);('index h= 1,2,3,4 denotes', 1);('serosurvey round', 1);('index l=', 1);('omicron vocs', 1);('12transmission model', 1);('stochastic compartmental metapopulation model d', 1);('pop- ulation', 1);('disease status', 1);('nd age', 1);('mobility dynamics', 1);('main model parameters', 1);('s hown', 1);('naivesusceptible individuals', 1);('s1', 1);('e1', 1);('averagelatent period', 1);('i1', 1);('new infectious cases', 1);('age-specic frac tionis', 1);('ir,1', 1);('iu,1', 1);('infectious indi- viduals', 1);('r1', 1);('average infectious period', 1);('infectious individuals', 1);('h1', 1);('age-specic rate', 1);('hospitalized', 1);('average age-specic hospitalization period', 1);('age- specic rate', 1);('upon', 1);('individuals return', 1);('susceptible compartment', 1);('age-specic rate voccurs', 1);('disease stages', 1);('infectio n', 1);('individuals reco', 1);('breakthrough infec- tion', 1);('hospitalization rate', 1);('er re-infection', 1);('model assumes', 1);('constant population size', 1);('study pe riod', 1);('themodelassumestheunreportedinfectedtravelandinfectot', 1);('population size', 1);('re gions', 1);('assumption equips', 1);('additional dynamics', 1);('case detection rate', 1);('acros s regions', 1);('sucient observations', 1);('time [ 27,62,63 ]', 1);('case detec tion rate', 1);('ny location', 1);('daily frequency', 1);('utch provinces', 1);('full description', 1);('model equations', 1);('schematic', 1);('metapopulation transmission mod el', 1);('model diagram', 1);('simplicit y', 1);('age-specic indices', 1);('14parameter inference', 1);('seroprevalenc e data', 1);('lter [', 1);('high-dimensional system', 1);('ecient way', 1);('large number o f ensembles', 1);('stochastic version', 1);('lter updates', 1);('ensemble member', 1);('form approximation akin', 1);('normal distribution', 1);('additional bias correction', 1);('large number', 1);('small number', 1);('par ameters', 1);('sect', 1);('parameter posteriors', 1);('variant periods', 1);('model', 1);('exact calculations', 1);('supplementary tables a9', 1);('a11a13', 1);('details', 1);('parameter identiability', 1);('verifysystem identiability forthe rstwave', 1);('param etersat', 1);('original sample', 1);('a14', 1);('o ur method', 1);('model seroprevalence', 1);('a15', 1);('figures a17a20', 1);('pa rameter congurations', 1);('original sample post erior', 1);('un til', 1);('parameter combination', 1);('w hich', 1);('sup', 1);('materials', 1);('figures a21 a23', 1);('c ase detection rates', 1);('15parameter changes', 1);('model inference tech nique', 1);('high uncertainty', 1);('supplementary figure a24', 1);('e ntire sample period', 1);('serosurvey data', 1);('primary inf ection', 1);('breakthrough infection/re-infection', 1);('seasonalit y', 1);('calibrations lead', 1);('available seroprevalen ce estimates', 1);('model estimation', 1);('tables a16a19', 1);('immunity wanes', 1);('aver age', 1);('reporting', 1);('research design', 1);('nature res', 1);('reporting summary', 1);('output datasets', 1);('input datasets', 1);('seropreva- lence data', 1);('seroprevalence data', 1);('fiona', 1);('ona.van.der.klis @ rivm.nl', 1);('eric vos', 1);('eric.vos.02 @ rivm.nl', 1);('bilthoven', 1);('nether-', 1);('b anninga', 1);('jan.banninga @ ns.nl', 1);('nederlandse spoorwegen ns', 1);('code', 1);('reposi- tory', 1);('16references [', 1);('dashboard', 1);('variation', 1);('infection-fatality ratio', 1);('d geography', 1);('pre-vaccine era', 1);('systematic analysis', 1);(':14691488. d oi:10.1016/s0140-6736', 1);('odriscoll', 1);('dos santos gr', 1);('wang', 1);('cummings dat', 1);('azman as', 1);('pair', 1);('immunity patterns', 1);(':1 40145. doi', 1);('//doi.org/10.1038/s41586- 020-2918-0', 1);('koelle k', 1);('martin ma', 1);('antia r', 1);('lopman', 1);('dean', 1);('epide miology', 1);(':11161121. doi:10.1126/science.abm4915', 1);('monod', 1);('blenkinsop', 1);('xi x', 1);('hebert d', 1);('bershan', 1);('tietze', 1);('davies ng', 1);('klepac p', 1);('prem k', 1);('pearson cab', 1);('age-d', 1);('ependent eects', 1);('nature medicine', 1);(':1 2051211. doi:10.1038/s41591-020-0962-9', 1);('perra n. non-pharmaceutical', 1);('physics', 1);('913:152. doi', 1);('morgenstern', 1);('kelly j', 1);('lowe r', 1);('ccw', 1);('jit m.', 1);('non-pharmaceutical interven- tions', 1);('territ ories', 1);(':4040. doi:10.1186/s12916-020-01872-8', 1);('rogers-smith', 1);('leech g', 1);('snodin', 1);('eec- tiveness', 1);('europe', 1);(':58205820. doi:10.1038/s41467-021-26013-4', 1);('brauner jm', 1);('johnston d', 1);('salvatier j', 1);('gaven', 1);('li y', 1);('campbell h', 1);('kulkarni d', 1);('harpur', 1);('nundy', 1);('temporal association', 1);('reproduction number', 1);('amodellingstudy across131countries', 1);('thelancetinfectiousdise', 1);('rozhnovag', 1);('bruijning-verhagenp', 1);('bootsmam', 1);('wijgert j', 1);('bonten', 1);('model-based', 1);('contro l', 1);('nature communi-', 1);(':1614. doi:10.1038/s41467-021-21899-6', 1);('flook', 1);('jackson', 1);('vasileiou e', 1);('simpson cr', 1);('muckian md', 1);('agrawal u', 1);('informing', 1);('public health response', 1);(':342342. doi:10.1186/s12879-021-05992-', 1);('bubar km', 1);('reinholt k', 1);('cobey', 1);('model-informed covid-19', 1);('vaccine prioritization strategies', 1);(':916921. doi:10.1126/science.abe6959', 1);('matrajt', 1);('eaton j', 1);('leung t', 1);('brown er', 1);('vaccine', 1);('optimization fo r', 1);('who', 1);('vaccinate rst', 1);('fitzpatrick mc', 1);('zimmer cf', 1);('abdollahi e', 1);('juden-kelly', 1);('mog', 1);('sm', 1);('asymptomatic sars- cov-2', 1);('proceedin', 1);('oce', 1);('statistics', 1);('infec', 1);('survey', 1);('//www.ons.gov.uk/surveys/informationforhouseh oldsandindividuals/householdandindividualsurveys/co vid19infectionsurvey', 1);('shioda k', 1);('lau msy', 1);('kraay anm', 1);('nelson kn', 1);('siegler aj', 1);('sullivan ps', 1);('estimating', 1);('cumulative inci-', 1);('infection fatality ratio', 1);('l ight', 1);('waning antibodies', 1);('hoz', 1);('paireau j', 1);('lapidus n', 1);('salje h', 1);('severi g', 1);('monitoring', 1);('hospitalisa tion', 1);('serological data', 1);('doi:10.1016 /s2468-2667', 1);('milne g', 1);('hames t', 1);('scotton', 1);('gent n', 1);('johnsen', 1);('anderson rm', 1);('does', 1);('lancet respirator', 1);(':14501466. doi:10.1016/s2213-2600', 1);('tracking sars-cov-2', 1);('//www.who.int/en/activities/tracking-sars-cov -2-variants/', 1);('townsend jp', 1);('lamb ad', 1);('hassler hb', 1);('nishio aa', 1);('nguyen', 1);('projectingthe', 1);('seasonalityof endemic', 1);('tedijanto', 1);('lipsitch m. projec', 1);('postpandemic period', 1);(':860868. doi:10.1126/science.abb5793', 1);('neher ra', 1);('dyrdakr', 1);('druelle v', 1);('hodcroft eb', 1);('albert j. potentia', 1);('asars-cov-2 pandemic', 1);('med wkly', 1);('150. doi:10.4414/smw.2020.20224', 1);('viana j', 1);('nunes', 1);('gomes mc', 1);('kretzsc', 1);('me', 1);('controlling', 1);('vaccination rollout', 1);(':3674. doi:10.1038/s41467- 021-23938-8', 1);('yamana tk', 1);('galanti', 1);('shaman j', 1);('c haracteristics', 1);(':338341. doi:10.103 8/s41586-021-03914-4', 1);('saad-roy cm', 1);('wagner ce', 1);('baker re', 1);('morris', 1);('farrar j', 1);('grah', 1);('al', 1);('immune', 1);('life history', 1);('year s. science', 1);(':811818. doi:10.1126/science.abd7343', 1);('lavine js', 1);('bjornstad on', 1);('antia r. immunological', 1);('characterist ics', 1);(':741745. doi:10.1126/scienc e.abe6522', 1);('sonabend r', 1);('whittles lk', 1);('imai n', 1);('perez-guzman pn', 1);('knock es', 1);('rawson t', 1);('non-pharmaceutical', 1);('delta variant', 1);('en', 1);(':18251835. doi:10.1016/s0140-67', 1);('dekker mm', 1);('pijpers fp', 1);('panja d', 1);('reducin', 1);('g societal impacts', 1);('inter- ventions', 1);('subnational implementation', 1);('doi:10 .1101/2022.03.31.22273222', 1);('gatto', 1);('carraro', 1);('casagrand', 1);('spread', 1);('eects', 1);('emergency containment measures', 1);(':1048410491. doi:10.1073/pnas.2004978', 1);('pasetto d', 1);('casagrandi r', 1);('gatt', 1);('o m', 1);('relaxationof connement measures', 1);(':4264. doi:10.1038/s41467-020-18050-2', 1);('giordano g', 1);('blanchini', 1);('bruno r', 1);('colaneri p', 1);('di filippo', 1);('di matt', 1);('population-wide interventions', 1);('ita', 1);('nature med', 1);('26:855860. doi:10.1038/s41591-020-0883-7', 1);('bosetti p', 1);('andronico', 1);('colizza v', 1);('yazdanpanah y', 1);('fontanet', 1);('france', 1);(':33. doi:10.1186/s12916-022-02235-1', 1);('de angelis d', 1);('goubar', 1);('gill on', 1);('ades ae', 1);('ev idence synthesis', 1);('trans- mission', 1);('dynamic model', 1);('hiv', 1);('biost', 1);(':666681. doi:10.1093/biostatistics/kxr006', 1);('birrell pj', 1);('ketsetzis g', 1);('gay nj', 1);('cooper bs', 1);('harris rj', 1);('a/h1n1pdm', 1);('london', 1);('proceedings', 1);('o f', 1);(':1823818243. doi:10.1073/pnas.1103002108', 1);('rozhnova g', 1);('kretzschmar me', 1);('baarle d', 1);('korn', 1);('dewal m', 1);('vossen ac', 1);('short-', 1);('long-term impact', 1);('18. doi', 1);('anderson jl', 1);('ensemble adjustment kalman filter', 1);('weather review', 1);(':2884 2903. doi:10.1175/1520-0493', 1);('aeakff2.0.co', 1);('shaman j. dierential', 1);('intervention timing', 1);('doi:10.1126/sc iadv.abd6370', 1);('mossong j', 1);('hens n', 1);('beutels p', 1);('auranen k', 1);('mikolajczyk r', 1);('social contacts', 1);('patterns relevantto', 1);('spreadofinfectious diseases', 1);('plosmedicine', 1);(':11. doi:10.1371/journal.pmed.0050074', 1);('mistry d', 1);('litvinova', 1);('pastore y piontti', 1);('chinazzi', 1);('fumanelli', 1);('gomes mfc', 1);('high-resolution human', 1);(':323323. doi:10.1038/s41467-020-20544-y', 1);('cevik m.', 1);('trans mission', 1);('viner rm', 1);('mytton ot', 1);('bonell', 1);('melendez-torresgj', 1);('ward j', 1);('hu', 1);('dson l', 1);('susceptibility', 1);('adolescents compared', 1);('s ystematic', 1);('review', 1);('meta-analysis', 1);('jama pediatrics', 1);(':143156. doi:10.1001/jamapediatric s.2020.4573', 1);('li r', 1);('chen', 1);('zhang t', 1);('yang', 1);('substantial', 1);('infection fa- cilitates', 1);('rapid dissemination', 1);('novel coronavirus', 1);(':489493. doi:10.1126/science.abb3221', 1);('sars-c', 1);('ov-2 variants', 1);('//www.ecdc.europa.eu/en/covid-19/variants-con cern', 1);('keeling mj', 1);('patterns', 1);('ars-cov-2', 1);('theoretical biology', 1);('miura', 1);('leung ky', 1);('wallinga j. optimal', 1);('va ccine allocation', 1);('data-driven prioritization', 1);('plos computat', 1);('biology', 1);(':113. doi:10.1371/journal.pcbi.1009697', 1);('backer j', 1);('boer p', 1);('hoek aj', 1);('alte', 1);('hk', 1);('disease outcomes', 1);('] van', 1);('hetebrij wa', 1);('swart', 1);('nagelkerkee', 1);('bee', 1);('rfhj', 1);('stouten', 1);('august', 1);('2020-febru ary', 1);('nationwide sewage surveillance program', 1);('schootuiterkampmhh', 1);('heesterbeekh', 1);('vanderh ofstadr', 1);('litvakn', 1);('theroleofinter-regionalmo-', 1);('roya', 1);('l society', 1);(':20220486. doi:10.1098/rsif.2022.0486', 1);('osgens m', 1);('hendriks t', 1);('boon', 1);('steenbakkers', 1);('heesterbe', 1);('hofstad r', 1);('trade-os', 1);('mobility restrictions', 1);('jou', 1);('royal society', 1);(':20200936. doi:10.1098/rsif.2020.0936', 1);('achieving', 1);('herd immunity', 1);('country level', 1);('exit strategy', 1);('scientic', 1);('brandspc', 1);('ojalj', 1);('azizar', 1);('werev', 1);('okiroea', 1);('kombeik', 1);('co vid-19transmissiondynamicsunderlying', 1);('epidemic waves', 1);('kenya', 1);(':989994. doi:10.1 126/science.abk0414', 1);('kishore n', 1);('taylor ar', 1);('jacob pe', 1);('vembar n', 1);('cohen t', 1);('buckee co', 1);('evaluating', 1);('mobility metrics', 1);('aggregatedmobile phone data', 1);('sars-co v-2', 1);('lancet digital', 1);('doi:10 .1016/s2589-7500', 1);('boldea', 1);('cornea-madeiraa', 1);('madeira j. disentangling', 1);('sars- cov-2 infections', 1);('dynamic intensity model', 1);('core', 1);('pr otocol', 1);('ecdc', 1);('stud- ies', 1);('vaccine eectiveness', 1);('se', 1);('acute respira-', 1);('infection', 1);('//www.ecdc.europa.eu/en/publications-data/cor e-protocol-ecdc-studies-covid-19-vaccine-effectiven ess-against-hospitalisation', 1);('cohen le', 1);('spiro dj', 1);('viboud c. projecting', 1);('tran sition', 1);('epidemiological', 1);('immunological considerations', 1);('plos p', 1);(':121. doi:10.1371/journal.ppat.1010591', 1);('bobrovitz n', 1);('ware h', 1);('ma x', 1);('li z', 1);('hosseini r', 1);('cao', 1);('protec', 1);('tive eectiveness', 1);('hybrid immunity', 1);('severe dis', 1);('meta- regression', 1);('vos era', 1);('hartog g', 1);('schepp rm', 1);('kaaijk p', 1);('vliet j', 1);('helm k', 1);('nationwide', 1);('general popula tion', 1);('rst epidemic wave', 1);('community health', 1);('doi:1 0.1136/jech-2020-215678', 1);('backer', 1);('mollema', 1);('vos er', 1);('klis fr', 1);('he', 1);('impact', 1);('phys- ical', 1);('p atterns', 1);('cross-sectional sur- veys', 1);('euro', 1);('doi:10.2807/1560- 7917.es.2021.26.8.2000994', 1);('li q', 1);('guan x', 1);('wu p', 1);('zhou', 1);('tong y', 1);('early', 1);('transmiss ion dynamics', 1);('wuhan', 1);('china', 1);('horta', 1);('liu j', 1);('schwieg t. estimating', 1);('econom', 1);(':106129. doi:10.1016/j.jeconom.2020.07.047', 1);('acknowledgements g.r', 1);('verdi', 1);('b y', 1);('views', 1);('digital', 1);('executive agency', 1);('c ao para', 1);('encia e', 1);('tecnologia', 1);('project 2022.01448.ptdc', 1);('sity fund', 1);('niaid', 1);('r01ai163023', 1);('cdc', 1);('contract 75d30122c142', 1);('prof. marc bonten', 1);('susan', 1);('van den', 1);('hof', 1);('instit', 1);('prof. dennis huisman', 1);('erasmus', 1);('rotterdam', 1);('jan ban', 1);('nederlandse spoorwegen', 1);('substantial help', 1);('bettina siinger', 1);('tilburg center liss panel survey', 1);('marino', 1);('zelst', 1);('wageningen', 1);('prof. jaap abbring', 1);('useful discussions', 1);('data availability', 1);('22author contributions', 1);('important feedback', 1);('computer c ode', 1);('o.b.', 1);('s.p.', 1);('competing', 1);('partial ownership', 1);('sk analytics', 1);('supplementarymaterialscontaindetailsofthedata', 1);('infe rence', 1);('supplementary figures', 1);('tables', 1);('correspondence correspondence', 1);('material requests', 1);('julius', 1);('cent er', 1);